DPP4 and metastatic prostate carcinoma: Dysregulation of the type II transmembrane glycoprotein dipeptidyl peptidase 4 (DPP4) has been implicated in several cancer types including urothelial carcinoma [10], papillary thyroid carcinoma [11], metastatic prostate cancer [12] and epithelial ovarian cancer [13].